来自MSN2 个月
Vir Biotechnology price target raised to $14 from $10 at JPMorgan
JPMorgan analyst Eric Joseph raised the firm’s price target on Vir Biotechnology (VIR) to $14 from $10 and keeps a Neutral rating on the shares. The firm believes initial clinical data for Vir ...